A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
Public ClinicalTrials.gov record NCT06764940. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Pivotal Phase II Clinical Trial of Utidelone Injection (UTD1) Plus Capecitabine (CAP) in HER2-negative Breast Cancer Patients With Brain Metastases
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is a multicenter, two-stage clinical trial to evaluate the efficacy and safety of utidelone in combination with capecitabine in patients with HER2-negative breast cancer with brain metastases. Patients will be enrolled to receive treatment of utidelone alone or in combination with capecitabine. The objectives both in stage I and stage II are to evaluate the intracranial and systemic efficacy and safety of utdelone plus capecitabine for the treatment of HER2-negative breast cancer patients with brain metastases.
Study identification
- NCT ID
- NCT06764940
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 120 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 13, 2025
- Primary completion
- Jan 14, 2027
- Completion
- Jul 14, 2027
- Last update posted
- Aug 20, 2026
2025 – 2027
United States locations
- U.S. sites
- 12
- U.S. states
- 8
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope--Duarte | Duarte | California | 91010 | Recruiting |
| Univ. of California Los Angeles | Los Angeles | California | 90095 | Recruiting |
| Scripps Health | San Diego | California | 92121 | Recruiting |
| University Of Colorado Hospital - Anschutz Cancer Pavilion | Aurora | Colorado | 80045 | Recruiting |
| Augusta University | Augusta | Georgia | 30912 | Recruiting |
| Robert H. Lurie Comprehensive Cancer Center Northwestern University | Chicago | Illinois | 60611 | Recruiting |
| The Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine | Baltimore | Maryland | 21287 | Recruiting |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89169 | Recruiting |
| Stony Brook Cancer Center | Stony Brook | New York | 11794-7263 | Recruiting |
| MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
| Community Clinical Trials | Kingwood | Texas | 22751 | Recruiting |
| Tranquil Clinical Research | Webster | Texas | 77598 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06764940, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 20, 2026 · Synced Sep 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06764940 live on ClinicalTrials.gov.